Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;13(1):10-8.
doi: 10.1007/s11882-012-0326-8.

Immunology and clinical manifestations of non-clonal mast cell activation syndrome

Juan-Carlos Cardet  1 , Mariana C Castells, Matthew J Hamilton
Affiliations
Review

Immunology and clinical manifestations of non-clonal mast cell activation syndrome

Juan-Carlos Cardet et al. Curr Allergy Asthma Rep. 2013 Feb.

Abstract

There is a spectrum of disorders that clinically manifest as a result of mast cell activation. A non-clonal form has emerged in the literature where many of the clinical features of systemic mastocytosis are shared despite having a distinct mast cell biology. In this review, we summarize key features of the science behind mast cell activation relevant to what is now known as non-clonal mast cell activation syndrome (nc-MCAS). We highlight the clinical manifestations of nc-MCAS with a focus on diagnosis and treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure No potential conflicts of interest relevant to this article were reported.

Figures

Fig 1
Fig 1
Electron microscopy images of a dermal mast cells before (left) and after (right) activation with degranulation. (Adapted from Weidner et al. [70] and Sheffer et al. [71]; with permission from Elsevier.)
Fig 2
Fig 2
Suggested flow diagram for the diagnosis of nc-MCAS
See this image and copyright information in PMC

References

    1. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. European journal of clinical investigation. 2007 Jun;37(6):435–453. PubMed PMID: 17537151. Epub 2007/06/01. eng. - PubMed
    1. Roberts LJ, 2nd, Oates JA. Biochemical diagnosis of systemic mast cell disorders. The Journal of investigative dermatology. 1991 Mar;96(3):19S–24S. discussion S-5S. PubMed PMID: 2002247. Epub 1991/03/01. eng. - PubMed
    1. Frieri M. Anaphylaxis. In: Raoof S, editor. Manual of Critical Care. Philadelphia, PA: American College of Physicians, McGraw Hill Co; 2009. pp. 721–730.

    1. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. The Journal of allergy and clinical immunology. 2010 Dec;126(6):1099–1104. e4. PubMed PMID: 21035176. Epub 2010/11/03. eng. • This article summarizes the consensus conference where experts proposed diagnostic criteria for non-clonal (idiopathic) mast cell activation syndrome as a distinct disease entity.

    1. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. Journal of hematology & oncology. 2011;4:10. PubMed PMID: 21418662. Pubmed Central PMCID: 3069946. Epub 2011/03/23. eng. - PMC - PubMed